Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 3Active not recruiting 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Arthritis, Rheumatoid 5Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Unresectable Pancreatic Carcinoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Multi-centric Castleman's Disease 1Melanoma 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Hodgkin Disease 1Hematologic Neoplasms 1Colitis 1Castleman Disease 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1

Interventions

Rituximab 187Cyclophosphamide 174Etoposide 94Peripheral Blood Stem Cell Transplantation 90Vincristine 89Prednisone 80Doxorubicin 79Filgrastim 75fludarabine phosphate 60Radiotherapy 56Mycophenolic Acid 41Melphalan 41Cytarabine 41Busulfan 40Cyclosporine 39Methotrexate 37Whole-Body Irradiation 36Tacrolimus 35Carmustine 34Ifosfamide 28Lenalidomide 27Granulocyte Colony-Stimulating Factor 27Antilymphocyte Serum 27Gemcitabine 25Carboplatin 25Methylprednisolone 24ibritumomab tiuxetan 23Bortezomib 22Dexamethasone 21ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Lymphoma, Large B-Cell, Diffuse × tocilizumab × Clear all
NCT05364424 2025-12-01

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Hoffmann-La Roche

Phase 1 Completed
43 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03677154 2025-08-21

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Hoffmann-La Roche

Phase 1/2 Completed
188 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02348216 2024-06-04

ZUMA-1

Gilead Sciences

Phase 1/2 Completed
307 enrolled 41 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡